The Stress-Response Sensor Chop Regulates the Function and Accumulation of Myeloid-Derived Suppressor Cells in Tumors  by Thevenot, Paul T. et al.
Immunity
ArticleThe Stress-Response Sensor Chop
Regulates the Function and Accumulation
of Myeloid-Derived Suppressor Cells in Tumors
Paul T. Thevenot,1 Rosa A. Sierra,1 Patrick L. Raber,1,2 Amir A. Al-Khami,1 Jimena Trillo-Tinoco,1 Parisa Zarreii,1
Augusto C. Ochoa,1,3 Yan Cui,1,2 Luis Del Valle,1 and Paulo C. Rodriguez1,2,*
1Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
2Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans,
LA 70112, USA
3Department of Pediatrics, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
*Correspondence: prodri1@lsuhsc.edu
http://dx.doi.org/10.1016/j.immuni.2014.08.015SUMMARY
Adaptation of malignant cells to the hostile milieu
present in tumors is an important determinant of their
survival and growth. However, the interaction be-
tween tumor-linked stress and antitumor immunity
remains poorly characterized. Here, we show the
critical role of the cellular stress sensor C/EBP-
homologous protein (Chop) in the accumulation
and immune inhibitory activity of tumor-infiltrating
myeloid-derived suppressor cells (MDSCs). MDSCs
lacking Chop had decreased immune-regulatory
functions and showed the ability to prime T cell
function and induce antitumor responses. Chop
expression in MDSCs was induced by tumor-linked
reactive oxygen and nitrogen species and regulated
by the activating-transcription factor-4. Chop-defi-
cient MDSCs displayed reduced signaling through
CCAAT/enhancer-binding protein-b, leading to a
decreased production of interleukin-6 (IL-6) and low
expression of phospho-STAT3. IL-6 overexpression
restored immune-suppressive activity of Chop-defi-
cient MDSCs. These findings suggest the role of
Chop in tumor-induced tolerance and the therapeu-
tic potential of targeting Chop in MDSCs for cancer
immunotherapy.
INTRODUCTION
Inflammatory mediators present in most individuals with cancer
inhibit antitumor immunity and represent a major limitation in the
development of different forms of immunotherapy (Coussens
et al., 2013). A characteristic of cancer-linked inflammation is
the accumulation of various immune inhibitory populations,
including myeloid-derived suppressor cells (MDSCs), regulatory
T (Treg) cells, and plasmacytoid dendritic cells (pDCs) (Chen and
Mellman, 2013). MDSCs represent a heterogeneous group of
myeloid precursors that impair the function of T cells, NK cells,
and DCs through several pathways including the expression ofImarginase I, inducible nitric oxide synthase (iNOS), and Gp91phox;
and the release of reactive oxygen species (ROS) and peroxyni-
trite (PNT) (Raber et al., 2012). In addition to their immunoregula-
tory activity, MDSCs also promote tumor angiogenesis and
metastasis (Gabrilovich et al., 2012). Two distinct subsets of
MDSCs have been identified in mice: granulocytic MDSCs
(G-MDSCs; CD11b+Ly6G+Ly6Cint) and monocytic MDSCs
(M-MDSCs; CD11b+Ly6GloLy6Chi), both characterized by the
expression of CD11b+Gr1+ (Movahedi et al., 2008). Although
the inhibitory role of MDSCs in antitumor immunity is well under-
stood, the central mechanisms governingMDSC function remain
poorly characterized, which has limited the development of stra-
tegies to globally block MDSC activity.
Transcription factors CCAAT/enhancer binding protein b
(C/EBPb) and phosphorylated signal transducer of activator of
transcription 3 (phospho-STAT3) centrally regulate MDSC func-
tion and expansion (Corzo et al., 2009;Marigo et al., 2010; Sonda
et al., 2013). Three isoforms of C/EBPb are generated from a
single mRNA through alternative protein synthesis (Descombes
and Schibler, 1991). C/EBPb isoforms liver-enriched activator
proteins (LAP* and LAP) function as transcriptional activators
of chronic inflammation-linked genes, such as interleukin-6
(IL-6) and arginase I (Marigo et al., 2010). Conversely, C/EBPb
liver-enriched inhibitory protein (LIP) lacks DNA transactivation
domains and reduces inflammation by blocking C/EBPb LAP
and LAP* signaling (Hattori et al., 2003). MDSC activity also
depends upon phospho-STAT3, which directly induces the
expression of arginase I and Gp91phox and the production of
ROS (Vasquez-Dunddel et al., 2013). Although the independent
role of C/EBPb and phospho-STAT3 in MDSCs has been
studied, the physiological mediators regulating C/EBPb and
phospho-STAT3 levels in tumor-infiltrating MDSCs remain
poorly described.
Metabolic activities in the tumor microenvironment lead to the
generation of a hostile milieu characterized by reduced oxygen
supply; limited availability of the amino acids arginine, cysteine,
and tryptophan; elevated production of ROS and PNT; low pH;
defects in glycoprotein and lipid biosynthesis; and glucose star-
vation linked to tumor glycolysis (Pearce et al., 2013). These
mediators of tumor-linked stress converge in common cellular
pathways collectively known as integrated stress responses
(ISR), which are characterized by the phosphorylation of themunity 41, 389–401, September 18, 2014 ª2014 Elsevier Inc. 389
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the induction of the activating transcription factor 4 (Atf4) and the
C/EBP homologous protein (Chop; encoded by Ddit3 and also
known as Chop-10 and Gadd153) (Harding et al., 2003; Rzymski
and Harris, 2007). Upregulation of Chop in tumors occurs after
chemo- or radiotherapy or as the result of the uncontrolled
growth of malignant cells (Scho¨nthal, 2013) and typically leads
to cellular apoptosis (Malhi and Kaufman, 2011). Elevated
expression of Chop in tumors correlated with stage, aggressive-
ness, and low survival in patients with different malignancies
(Dalton et al., 2013; Kim et al., 2012). Furthermore, decreased
liver carcinoma development was observed in Chop-deficient
mice, which associated with reduced amounts of various cyto-
kines (Scaiewicz et al., 2013; DeZwaan-McCabe et al., 2013).
An initial report suggested the role of stress-linked responses
on the function of MDSCs (Condamine et al., 2014). However,
the specific role of Chop in the modulation of antitumor immunity
remains unknown.
We aimed to determine the role of tumor-stromal Chop in the
suppression of immune responses in tumor-bearing hosts. Our
results demonstrate the critical role of Chop in the accumulation
and immune-regulatory function of MDSCs in tumors. MDSCs
lacking Chop had a low capacity to block T cell responses, an
impaired expression of major inhibitory pathways, and a high
ability to prime T cell function and induce antitumor effects.
Chop upregulation in MDSCs was mediated by tumor-induced
ROS and PNT and favored the expression of IL-6 and the
MDSC regulators C/EBPb and phospho-STAT-3. Also, ectopic
expression of IL-6 restored tumor growth and MDSC activity in
Chop-deficient mice. These results show the checkpointsmodu-
lating the interaction between tumor-induced stress andMDSCs
in the suppression of antitumor immunity and suggest targeting
stromal Chop as a means to overcome tumor-induced tolerance
and to enhance the efficacy of immunotherapy in cancer.
RESULTS
Expression of Chop in Tumor-Infiltrating MDSCs
Regulates Tumor Growth
The role of Chop in antitumor immunity and its distribution within
tumor cell populations remains unknown. Therefore, we first
compared the expression of Chop in spleens and tumors fromFigure 1. Stromal Chop Deletion Delays Tumor Progression in a MDSC
(A) Chop levels in specific stromal cell populations sorted by flow cytometry from
(B) Chop expression in splenic and tumor MDSCs recovered from mice bearing
carcinoma. Immature myeloid cells (iMCs) were obtained by sorting CD11b+Gr1
(C) Immunofluorescence detection of Chop (Alexa Fluor 488 secondary antibody
biopsies from advanced colon carcinoma patients. A representative slide from 2
(D) Immunofluorescence detection of Chop (Alexa Fluor 590 in red), CD66b (Alex
(E) Tumor growth kinetics in wild-type (WT; closed square) andDdit3/ (closed tri
MCA-38 colon carcinoma. Average kinetics ± SEM of ten mice per group from t
(F) Lethally irradiated wild-type CD45.1+ mice received bone marrow transplant
(Ddit3/ /WT, blue open triangle). Seven weeks after transplant, chimeric
Ddit3/CD45.2+ (Ddit3/, closed red triangle) mice were injected s.c. with 3L
CD45.2+ wild-type (WT/WT, green open square) or CD45.2+Ddit3/ (WT/ D
marrow and injected s.c. with 3LL cells after 8 weeks together with nonirradi
experiments.
(G) 3LL-bearing wild-type andDdit3/mice were injected either with anti-Gr1 or i
In all panels ***p < 0.001. See also Figure S1.
Immice s.c. injected with 3LL lung carcinoma. An increased
expression of Chop was found at the tumor site, compared to
the spleen (Figure S1A available online), and was shared by the
malignant cells and infiltrating CD45+ leukocytes (Figure S1B).
To identify the distribution of Chop among the tumor-linked leu-
kocytes, we sorted different CD45+ populations from 3LL tumors
and monitored their expression of Chop. Higher amounts of
Chop were found in MDSCs (CD11b+Gr1+) compared to other
cell populations, including CD11b+Gr1 myeloid cells, CD11b+
CD11c+ dendritic cells, CD11b+F4/80+ macrophages, B220+ B
lymphocytes or pDCs, and CD3+ T cells (Figure 1A). Moreover,
the increased expression of Chop in tumor-linked MDSCs,
compared to splenic MDSCs or immature myeloid cells (iMCs),
was validated in different tumor models, including 3LL, B16
(melanoma), EL-4 (thymoma), and MCA-38 (colon carcinoma)
(Figure 1B), and correlated with the MDSC ability to block
T cell proliferation (Figure S1C). Next, we tested whether human
MDSCs infiltrating tumors displayed an increased expression of
Chop. Using a panel of colon carcinoma samples, we found a
preferential Chop upregulation in CD33+ myeloid cells, which
were found in minimal numbers in normal colon tissues (Figures
1C and S1D). In addition, Chop expression in colon tumors was
restricted to CD66b+HLA-DR populations (Figure 1D; Tal-
madge and Gabrilovich, 2013), demonstrating the expression
of Chop in human MDSCs.
To determine the effect of stromal Chop in tumor growth,
C57BL/6 controls andChop-deficient mice (referred asDdit3/)
were injected s.c. with different tumors carrying functional Chop,
after which tumor growth kinetics and survival were monitored.
In all tested tumormodels, a decreased tumor growth (Figure 1E)
and an extended survival (Figure S1E) were noticed in Ddit3/
mice, compared to wild-type controls. In addition, increased tu-
mor cell necrosis and decreased angiogenesis were observed in
tumors from Ddit3/ mice (Figures S1F and S1G). However,
endothelial cells (CD31+CD45CD11b) sorted from tumors dis-
played a limited expression of Chop, ruling out a direct effect of
Chop in tumor endothelium (Figure S1H). Because MDSCs were
the major source of Chop in the tumor stroma, we established
their role in the antitumor effects found in Ddit3/ mice, using
a bone marrow (BM) chimeric model (Loinard et al., 2012). In
brief, lethally irradiated CD45.1+ mice were reconstituted with
BM cells isolated from CD45.2+Ddit3/ mice or controls.-Dependent Manner
single-cell suspensions of s.c. 3LL tumors 18 days after injection.
s.c. 3LL lung carcinoma, B16 melanoma, EL-4 thymoma, or MCA-38 colon
+ cells from spleens of mice without tumors.
in green) and CD33+ (Alexa Fluor 590 secondary antibody in red) in a panel of
4 patients.
a Fluor 488 in green), and HLA-DR (Alexa Fluor 647 in pink) in tissues from (C).
angle) mice bearing s.c. 3LL lung carcinoma, B16melanoma, EL-4 thymoma, or
wo replicates.
s from CD45.2+ wild-type (WT/WT, green open square) or CD45.2+Ddit3/
mice and nonirradiated wild-type CD45.2+ (WT, closed black square) or
L cells and tumor growth monitored. For reversal studies, lethally irradiated
dit3/, blue open triangle) were transplanted with CD45.1+ wild-type bone
ated controls. Results expressed as mean ± SEM from ten mice from two
sotype antibody (i.p. 200 mg/mouse every 4 days) and tumor growth monitored.
munity 41, 389–401, September 18, 2014 ª2014 Elsevier Inc. 391
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transplanted with CD45.1+ wild-type BM cells. Greater than
90% chimerism (Figures S1I and S1J) and equal numbers of
CD11b+Gr1+ cells (data not shown) were found in all conditions
7 weeks after transplant. A similar delay in tumor growth was
found in Ddit3/ BM chimeric mice and systemic Ddit3/
mice, as compared to controls (Figure 1F). In addition, reconsti-
tution of Ddit3/ mice with wild-type BM resulted in a similar
tumor growth as that observed in wild-type controls (Figure 1F),
suggesting the key role of MDSC-linked Chop in tumor growth.
To further demonstrate the role of MDSCs in the antitumor
effects found in Ddit3/ mice, we depleted MDSCs by treat-
ment with anti-Gr1 antibodies (Mundy-Bosse et al., 2011). Phar-
macological depletion of MDSCs induced antitumor effects in
wild-type mice, while it resulted in a partial recovery of tumor
growth in 3LL-bearing Ddit3/ mice (Figure 1G), suggesting
the functional difference between MDSCs from tumor-bearing
wild-type and Ddit3/ mice. Thus, our results suggest that
tumor MDSCs display a preferential increased expression of
Chop and that deletion of Chop induced antitumor effects in a
MDSC-dependent manner.
Chop Regulates the Proliferation, Turnover, and
Immune-Inhibitory Activity of MDSCs
We tested the impact of Chop in the accumulation, turnover, and
immune inhibitory function of MDSCs. Similar percentages of
MDSCs were found in the spleen and BM of wild-type and
Ddit3/ mice with and without tumors (Figures S2A and S2B).
In contrast, an elevated percentage of MDSCs was detected in
tumors from Ddit3/ mice, compared to controls, with both
G-MDSCs and M-MDSCs showing increases (Figure 2A). Inter-
estingly, the accumulation of tumor MDSCs in Ddit3/ mice
did not extend to other myeloid populations, such as DCs
(CD11b+Gr1CD11c+) and macrophages (CD11b+Gr1F4/80+)
(Figures S2C and S2D). To test the specific role of Chop in
MDSC accumulation in tumors, BM MDSCs were harvested
from 3LL-bearing wild-type and Ddit3/ mice, labeled with
high and low concentrations of CFSE, mixed in a 1:1 ratio, and
adoptively transferred into wild-type mice bearing 3LL cells. At
24 hr after transfer, we found similar amounts of transferred
wild-type and Ddit3/ MDSCs in spleen, while higher numbers
of Ddit3/MDSCs were noted in tumors (Figure 2B). To further
understand the increased accumulation of Ddit3/ MDSCs in
tumors, we investigated the effect of Chop in the proliferation
and decay of MDSCs. A similar proliferation of spleen and
bone marrow MDSCs was found in wild-type and Ddit3/
mice, as tested by BrdU uptake (Figures S2E and S2F). In
contrast, an elevated tumor MDSC proliferation was noted in
Ddit3/ mice, compared to controls (Figure 2C). Moreover,
decreased expression of the apoptosis markers annexin V and
cleaved caspase 3 (Figure 2D) were detected in tumor MDSCs
from Ddit3/ mice, compared to wild-type MDSCs. Thus,
Chop deletion increased proliferation and reduced turnover of
tumor MDSCs.
We then asked whether Chop deletion affected the immune-
inhibitory ability of MDSCs. Tumor-sorted MDSCs from Ddit3/
mice had a reduced capacity to block activated T cell prolifera-
tion and IFN-g production, as compared to those from control
mice (Figure 2E). A similar decreased inhibitory function was392 Immunity 41, 389–401, September 18, 2014 ª2014 Elsevier Inc.also detected in MDSCs from tumor-bearing Ddit3/ BM chi-
meras (Figure 2F). Interestingly, the low regulatory potential of
Ddit3/MDSCs correlated with an impaired synthesis of major
molecules linked to MDSC activity, including arginase I, PNT,
and superoxide, but an increased iNOS expression (Figure 2G).
To test the role of Chop in the tolerogenic activity of MDSCs
in vivo, CD45.2+ anti-OVA257-264 (SIINFEKL) transgenic CD8
+
OT-I cells were adoptively transferred into CD45.1+ mice, fol-
lowed by immunization with wild-type DCs loaded with
SIINFEKL. Tumor MDSCs from wild-type or Ddit3/ mice
pulsed with SIINFEKL were transferred the same day as immuni-
zation, as well as 5 days later (Dolcetti et al., 2010). Transferred
MDSCs had a similar low contamination with CD11c+ DCs and
F4/80+ macrophages (Figures S2G–S2I). At 12 days after vacci-
nation, lymph nodes were harvested, challenged with SIINFEKL,
and tested for IFN-g production by Elispot. A significant
decrease in the production of IFN-g was found in mice trans-
ferred with SIINFEKL-loaded DCs and wild-type MDSCs (Fig-
ure 2H). Conversely, transfer of Ddit3/ MDSCs further
enhanced the numbers of IFN-g+ cells induced by the
SIINFEKL-DCs vaccine, suggesting that Chop deletion not only
blocked the tolerogenic activity of MDSCs, but also allowed
MDSCs to increase T cell function.
Chop-Deficient MDSCs Induce Antitumor Responses
and Prime T Cell Proliferation
We hypothesized that deletion of Chop in MDSCs enables them
to induce antitumor responses. Therefore, 3LL cells were mixed
1:1withMDSCs isolated fromwild-type orDdit3/mice bearing
3LL tumors and injected s.c. into wild-type or Ddit3/ mice.
Coinjection of Ddit3/ MDSCs into wild-type mice significantly
delayed tumor growth, whereas coinjection of wild-type MDSCs
into Ddit3/ mice partially restored tumor growth (Figure 3A).
We next evaluated the therapeutic effect of Ddit3/ MDSCs in
established tumors. Adoptive transfer of Ddit3/ MDSCs after
3 and 6 days of 3LL injection delayed tumor growth, while trans-
fer of wild-type MDSCs accelerated 3LL growth (Figure 3B). A
possible explanation for these results could be that Ddit3/
MDSCs directly killed tumor cells. However, a low antitumor
cytotoxicity was displayed by wild-type and Ddit3/ MDSCs
(Figure 3C), ruling out a direct antitumor effect of Ddit3/
MDSCs. Alternatively, we tested whether Chop deletion allowed
MDSCs to prime T cell responses. Thus, MDSCs were sorted
from wild-type and Ddit3/ mice bearing 3LL tumors, after
which they were loaded with SIINFEKL, washed, and cocultured
with CFSE-labeled naive OT-I cells. A higher proliferation was
observed in OT-I cells cocultured with Ddit3/ MDSCs,
compared to those coculturedwithwild-typeMDSCs (Figure 3D),
suggesting that Chop deletion enabled MDSCs to induce T cell
proliferation. In fact,Ddit3/MDSCs displayed a higher expres-
sion of major histocompatibility complex (MHC) class I and II
(Figure 3E). Thus, Chop-deficient MDSCs induced antitumor
effects and had the ability to activate T cell responses.
Chop in MDSCs Is a Central Mediator of Tumor-Induced
Tolerance
We then determined whether the deletion of stromal Chop
impacted the suppression of T cell responses in tumors. We
found in tumor-bearing Ddit3/ mice an increased infiltration
Figure 2. Chop Deletion in MDSCs Decreases Turnover, Increases Proliferation, and Blocks Immune Tolerogenic Function
(A) Percentage of MDSCs (CD11b+Gr1+) as well as granulocytic (G-MDSCs; CD11b+Ly6G+Ly6Cint) and monocytic (M-MDSCs; CD11b+Ly6GloLy6Chi) subsets in
wild-type and Ddit3/ mice bearing s.c. 3LL tumors for 17 days.
(B) Bone-marrowMDSCs sorted fromwild-type andDdit3/ 3LL tumor-bearingmicewere labeled with high or low concentration of CFSE, respectively, mixed in
a 1:1 ratio, and coinjected i.v. into wild-type 3LL-bearing mice. Transferred MDSC accumulation was monitored in the spleen and tumor 24 hr after injection.
Representative plot from two experiments (n = 5).
(C) Wild-type and Ddit3/ mice bearing 3LL tumors for 16 days were injected i.p. with BrdU and the percentage of BrdU+ MDSCs (gated within CD11b+Gr1+)
calculated 24 hr later by flow cytometry. Results are mean ± SEM of five mice per group in three independent experiments.
(D) Percentage of annexin V+ MDSCs and expression of cleaved and total caspase 3 in tumor MDSCs from wild-type and Ddit3/mice bearing 3LL tumors for
17 days. Representative plots from three experiments (n = 10).
(E) CFSE-labeled CD3+ T cells activated with anti-CD3/CD28 were cocultured at different ratios with MDSCs isolated from wild-type and Ddit3/mice bearing
s.c. 3LL tumors for 17 days. Proliferation and IFN-g expression in T cells wasmonitored 72 hr later. Results are expressed asmean ± SEM from tenmice per group
from two independent experiments.
(F) CD3+ T cells were activated with plate-bound anti-CD3/CD28 and cocultured in a ratio of 1:1/4 with MDSCs sorted from wild-type, Ddit3/, or Ddit3/ bone
marrow chimeric mice bearing 3LL cells for 17 days. Mean ± SEM from three experiments.
(G) Immunoblot for arginase I and inducible nitric oxide synthase in isolated MDSCs. ELISA for PNT in MDSCs protein lysates. Assay of superoxide production in
isolated MDSCs. All assessments performed on MDSCs isolated from wild-type or Ddit3/ 3LL tumor-bearing mice 18 days after s.c. injection. Data plotted are
pooled values from three experiments (n = 5).
(H) IFN-g Elispot (representative images in left panel) of SIINFEKL-challenged lymph node cells fromwild-type CD45.1+mice that received i.v. transfer of CD45.2+
OT-I cells, SIINFEKL-loaded DCs, and SIINFEKL-pulsed MDSCs from wild-type or Ddit3/ mice. Data are expressed as mean ± SEM from three experiments
having five independent samples.
In the figures, **p < 0.01, ***p < 0.001. See also Figure S2.
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ure 4A) and an elevated number of CD8+ T cells producing
IFN-g after activation (Figure 4B). Furthermore, a partial recoveryImof CD3z chain expression, a key protein for T cell activation, was
observed in T cells from 3LL-bearing Ddit3/ mice, compared
to those from controls with tumors (Figure 4C). Although T cellsmunity 41, 389–401, September 18, 2014 ª2014 Elsevier Inc. 393
Figure 3. Chop-Deficient MDSCs Delay Tumor Growth and Promote T Cell Function
(A) Tumor growth in wild-type (left panel, closed symbols) andDdit3/ (right panel, open symbols) mice injectedwith 3LL cells alone (closed and open squares) or
coinjectedwith tumorMDSCs fromwild-type (closed and open diamonds) orDdit3/ (closed and open triangles)mice. Coinjected cells weremixed at a 1:1 ratio.
Plots are from ten mice from two experiments.
(B) Tumor growth kinetics in control wild-type mice (3LL alone, squares) or mice receiving i.v. transfer of wild-type (diamonds) or Ddit3/ (circles) MDSCs
(3 3 106) on days 3 and 6 after 3LL injection.
(C) LDH cytotoxicity assay of 3LL tumor cells after 6 hr of coculture with MDSCs from wild-type or Ddit3/mice bearing s.c. 3LL tumors for 17 days. Results are
from three replicates (n = 10).
(D) Proliferation of CFSE-labeled CD8+ OT-I cells after 72 hr of priming with SIINFEKL-pulsed MDSCs from wild-type or Ddit3/mice (2 mg/ml for 4 hr). Results
are from three replicate experiments.
(E) Mean fluorescent intensity (MFI) of MHC-I and MHC-II in tumor MDSCs from wild-type or Ddit3/ mice. Data are expressed as mean ± SEM from three
replicates.
In the plots, ***p < 0.001.
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we tested their effect as mediators of the antitumor responses
found in Ddit3/ mice. Depletion of CD8+ T cells, but not
CD4+ T cells, restored tumor growth in 3LL-bearing Ddit3/
mice (Figure 4D), suggesting a potential role of CD8+ T cells in
the antitumor responses induced by Chop deletion.
To address the role of Chop in tumor-induced tolerance, wild-
type and Ddit3/ mice (CD45.2+) were injected s.c. with 3LL
tumors expressing the model tumor antigen ovalbumin (OVA).
Seven days later, 5 3 106 CD45.1+CD8+ OT-I cells were adop-
tively transferred into the mice, followed by vaccination with
SIINFEKL. A higher antitumor effect was noted in Ddit3/
mice receiving OT-I cells, as compared to wild-type controls
transferred with the same number of T cells (Figure 4E). In addi-
tion, elevated numbers of T cells producing IFN-gwere detected
in the spleens of vaccinated tumor-bearing Ddit3/ mice after
activation ex vivo with SIINFEKL (Figure 4F), which correlated394 Immunity 41, 389–401, September 18, 2014 ª2014 Elsevier Inc.with a higher total yield of transferred CD45.1+ OT-I cells in
both the spleens and tumors (Figure 4G). Because these results
could be explained by a low suppression driven by the smaller
tumors observed in Ddit3/ mice, we repeated the experiment
in wild-type and Ddit3/ mice bearing similar sized 3LL-OVA
tumors (100 mm3, day 8 for wild-type and day 15 for Ddit3/
mice). An increased production of IFN-g+ after SIINFEKL activa-
tion (Figure 4H) and higher numbers of CD45.1+OT-I T cells in the
spleens and tumors (Figure 4I) were detected in tumor-bearing
Ddit3/ mice, compared to controls, suggesting the key role
of Chop in tumor-induced tolerance and the potential benefit
of its deletion for T cell-based immunotherapy.
Mediators of Chop Expression in MDSCs
We investigated the role of the tumor environment in the induc-
tion of Chop in MDSCs and the effect of Chop in the promotion
of MDSC function by tumors. BM MDSCs (Marigo et al., 2010)
Figure 4. Chop Deletion Overcomes Tumor-Induced T Cell Tolerance and Enhances T Cell Immunotherapy
(A) Percentage of CD45+CD3+CD8+ T cells in single-cell suspensions of 3LL tumors from wild-type and Ddit3/ mice after 17 days of tumor injection.
(B) Percentage of IFN-g-expressing splenic T cells obtained from wild-type or Ddit3/ tumor-bearing mice and activated in vitro with anti-CD3/CD28 for 48 hr.
(C) Mean fluorescent intensity (MFI) of CD3z in splenic CD3+ T cells from wild-type and Ddit3/ mice bearing or not s.c. 3LL tumors for 17 days.
(D) Tumor growth in 3LL tumor-bearing wild-type andDdit3/mice treatedwith antibodies against CD8+ or CD4+ T cells (isotype, square; anti-CD4, triangle; anti-
CD8, circle). Data from five mice per group.
(E) Wild-type andDdit3/ (CD45.2+) mice bearing s.c. 3LL-OVA tumors for 7 days were left untreated or received adoptive transfer with naive CD45.1+CD8+ OT-I
cells (5 3 106), followed by immunization with SIINFEKL. Then, they were followed for tumor growth. Closed square, wild-type (WT) no adoptive transfer; open
square, WT plus OT-I adoptive transfer; closed triangle, Ddit3/ no adoptive transfer; open triangle, Ddit3/ plus OT-I adoptive transfer.
(F and G) CD45.2+ wild-type andDdit3/mice bearing 3LL-OVA tumors for 7 days received 53 106 CD45.1+ OT-I cells, followed by vaccination using SIINFEKL.
(F) Spleens were harvested 10 days later and challenged in vitro with 2 mg/ml SIINFEKL, after which the percentage of IFN-g-producing cells was assessed by
Elispot. Top panel is representative of the cultures. Bottom panel is grouped INF-g production from ten mice ± SEM.
(G) Spleens and tumors were harvested 10 days after the OT-I cell adoptive transfer and tested for the presence of transferred CD45.1+CD8+ OT-I cells in the
spleen and tumor. Representative density plots (left panel) and percentage of cells (right panels) (n = 10).
(H and I) Endpoints as in (F) and (G) were obtained from wild-type and Ddit3/mice receiving adoptive cellular therapy and vaccination when they were bearing
equal sized tumors of 3LL-OVA. Elispot results from ten mice per group from three independent experiments.
In the panels, *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S3.
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Figure 5. Tumor-Derived Stress Factors Trigger Chop Expression in MDSCs
(A) Chop expression in BM MDSCs generated after culture of bone marrow precursors with G-CSF (100 ng/ml) and GM-CSF (20 ng/ml) and treated with tumor
explant supernatants (TES) during the last 24 hr. TES was obtained from cell-free supernatants of wild-type 3LL tumor digests incubated overnight at 1 3 107
cells/ml.
(B) Coculture of CFSE-labeled T cells with TES-primed wild-type and Ddit3/ BM MDSCs at a 1:1/4 ratio for 72 hr. Proliferation calculated by CFSE and
normalized to activated T cells without BM MDSCs coculture.
(C) Chop expression in BM MDSCs exposed during the last 24 hr of culture to PNT (250 mM) or hydrogen peroxide (250 mM).
(D) Chop expression in BM MDSCs ± 40% TES with or without the addition of 2 mM L-NAC, 100 mM PTIO, or 100 mM MnTBAP.
(E) Chop and arginase I expression in MDSCs from 3LL-bearing mice treated daily i.p. with PBS or 1 mg/kg L-NAC.
(F) Tumor progression in mice with PBS or 1 mg/kg L-NAC. n = 10 from 2 experiments.
(G) Proliferation of CFSE-labeled T cells 72 hr after coculture with different numbers of tumor MDSCs recovered from PBS- or L-NAC-treated 3LL tumor-
bearing mice.
(H) ELISA for nitrotyrosine in extracts prepared from single-cell 3LL tumor digests as well as MDSC-sorted and MDSC-depleted fractions.
(I) Expression of Chop in TES-treated wild-type and Gp91phox/ BM MDSCs.
In all panels, data are expressed as mean ± SEM from a representative experiment of three replicates. ***p < 0.001. See also Figure S4.
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whichMDSCswere tested for the induction of Chop and the abil-
ity to block T cell proliferation. TES treatment induced Chop
expression in MDSCs (Figure 5A) and increased MDSC regula-
tory activity (Figure 5B). Interestingly,Ddit3/BMMDSCs failed
to increase inhibitory function after TES treatment (Figure 5B),
suggesting the role of Chop in the regulation of MDSC function
by tumors. To identify themajor mediators leading to the expres-
sion of Chop in MDSCs, we initially tested the effect of ROS and
PNT. Higher amounts of PNT and ROS were found in tumors,
compared to spleens of 3LL-bearing mice and controls (Figures
S4A and S4B), and in tumorMDSCs compared to spleenMDSCs
and iMCs (Figures S4C and S4D). In addition, treatment of BM
MDSCs with PNT, and to a lesser extent with H2O2, led to a
similar induction of Chop as that induced by TES (Figure 5C).
In agreement with these data, inhibition of Chop upregulation396 Immunity 41, 389–401, September 18, 2014 ª2014 Elsevier Inc.was noted in TES-treated BM MDSCs after the addition of
antioxidant N-acetyl cysteine (L-NAC) and PNT scavenger
MNTBAP, but not nitric oxide scavenger PTIO (Figure 5D). More-
over, treatment of tumor-bearing mice with L-NAC resulted in a
lower expression of Chop in tumor MDSCs (Figure 5E) and a
similar effect as that induced by Chop deletion, including a de-
layed tumor growth (Figures 5F and S4E), an impaired MDSC
inhibitory function (Figure 5G), and reduced levels of arginase I
(Figure 5E). Because MDSCs were a major source of PNT in tu-
mors (Figure 5H), we aimed to determine whether the endoge-
nous production of ROS or PNT in MDSCs modulated Chop.
Deletion of Gp91phox, a key component in the production of
ROS and PNT by MDSCs (Corzo et al., 2009), blocked Chop up-
regulation in TES-treated BMMDSCs (Figure 5I), suggesting the
endogenous role of ROS or PNT in MDSCs in the induction of
Chop by tumors.
Figure 6. Atf4 Regulates Tumor-Induced
Chop Expression in MDSCs
(A) Phosphorylation of eIF2a (left) and mRNA
expression of Atf4 (center) in tumor MDSCs
(tMDSCs) and spleen MDSCs (sMDSCs) from 3LL-
bearing mice or immature myeloid cells (iMCs)
from controls. eIF2a phosphorylation in iMCs
cultured for 24 hr in the presence of TES or spleen
explants supernatant (SES) (right).
(B) ChIP assay of MDSCs-chromatin immunopre-
cipitated using anti-Atf4 antibodies and assayed
for Chop promoter by RT-PCR. Data from n = 5
mice per group.
(C) Expression of Chop in TES-treated wild-type
and Atf4+/ BM MDSCs.
(D and E) Atf4 mRNA and Chop expression in tu-
mor MDSCs from wild-type and Atf4+/ bearing
s.c. 3LL tumors. Data from five mice per group.
(F) Tumor growth in wild-type (WT; closed square)
and Atf4+/ mice (closed triangle) bearing 3LL tu-
mors. Average kinetics ± SEM of ten mice per
group from two replicates.
In the figure, **p < 0.01, ***p < 0.001.
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ISRs are characterized by the expression of phospho-eIF2a and
signaling through Atf4 protein. We aimed to determine the role of
ISR in the induction of Chop in MDSCs. Increased expression of
phospho-eIF2a and Atf4 were noted in MDSCs from tumors and
TES-treated BM MDSCs (Figure 6A). Furthermore, the elevated
expression of Chop in tumor-linked MDSCs correlated with a
higher endogenous binding of Atf4 to Chop promoter, as tested
by ChIP assays (Figure 6B). To confirm the role of Atf4 in the in-
duction of Chop in MDSCs from tumors, we used Atf4+/ mice,
because Atf4/ mice showed low survival. Treatment of
Atf4+/ BM MDSCs with TES resulted in an impaired induction
of Chop (Figure 6C). In addition, MDSCs isolated from 3LL-
bearing Atf4+/ mice showed a 50% decrease in Atf4 induction
(Figure 6D) and a reduction in the expression of Chop (Figure 6E),
suggesting the role of Atf4 as amajor mediator of Chop induction
in MDSCs from tumors. Interestingly, partial deletion of Atf4 trig-
gered a similar antitumor effect as that found in Ddit3/ mice
(Figure 6F). Thus, the induction of Chop in tumor MDSCs was
mediated by induction of Atf4.
Chop Regulates MDSC Activity by Modulating IL-6
We sought to understand the mechanisms by which the deletion
of Chop impaired MDSC function. Previous studies showed the
role of C/EBPb in MDSC function (Marigo et al., 2010) and of
Chop in C/EBPb activity (Hattori et al., 2003). Thus, we hypothe-
sized that Chop deletion impaired C/EBPb signaling in MDSCs.
Similar levels of C/EBPb mRNA were found in wild-type and
Ddit3/ MDSCs from tumors (Figure 7A). Conversely, a higher
expression of the inhibitory form C/EBPb LIP, without changes
in C/EBPb LAP and LAP*, was found in Ddit3/ MDSCs,
compared to controls (Figure 7A). A similar elevation of
C/EBPb LIP was also noted in MDSCs from L-NAC-treated
mice, suggesting the role of ROS or PNT as mediators of thisImpathway (Figure 7B). Translation of C/EBPb LIP in MDSCs is
favored by the expression of microRNA 142-3p (miR-142-3p)
(Sonda et al., 2013). Accordingly, higher levels of miR-142-3p
were detected in Ddit3/ MDSCs, compared to controls (Fig-
ure 7C). Furthermore, Ddit3/ MDSCs had decreased C/EBPb
activity, as tested by DNA-binding ELISA (Figure 7D), and in-
hibited endogenous binding of C/EBPb to IL-6 and arginase I
promoters, measured by ChIP assay (Figure 7E). The reduced
binding of C/EBPb to IL-6 promoter in Ddit3/ MDSCs trans-
lated into a decreased production of IL-6 (Figure 7F) and lower
expression of IL-6 receptor-linked protein, phospho-STAT3 (Fig-
ure 7G). However, similar expression of IL-6 receptors gp126
and gp130 (Figure S5A) in tumor MDSCs and equal induction
of phospho-STAT3 in response to exogenous IL-6 (Figure S5B)
were found in wild-type and Ddit3/ MDSCs, suggesting that
a decrease in IL-6 rather than a low sensitivity to IL-6 was modu-
lated by Chop knockdown.
To determine the significance of the low expression of IL-6 in
the antitumor effects induced by Chop deletion, 3LL cells over-
expressing IL-6 (3LL-IL-6) were injected into wild-type and
Ddit3/mice. Ectopic expression of IL-6 restored tumor growth
in Ddit3/ mice (Figure 7H). In addition, MDSCs from Ddit3/
mice bearing 3LL-IL-6 tumors were equally suppressive as con-
trol MDSCs from 3LL or 3LL-IL-6-bearing mice (Figure 7I).
Furthermore, the decreased levels of phospho-STAT3 observed
in Ddit3/MDSCs were partially restored after ectopic expres-
sion of IL-6 in tumor cells (Figure 7J). These suggest the rele-
vance of IL-6 in the antitumor effects induced by MDSC-Chop
deletion.
DISCUSSION
Although an adequate ISR in tumor cells is fundamental for their
growth and survival in vivo (Rouschop et al., 2010; Ye et al.,munity 41, 389–401, September 18, 2014 ª2014 Elsevier Inc. 397
Figure 7. Deletion of Chop Blocks Tumor Growth and MDSC Function through Inhibition of IL-6 Production
(A) Expression of C/EBPb mRNA in tumor MDSCs sorted from wild-type and Ddit3/ mice bearing 3LL tumors (left). C/EBPb isoform LAP, LAP*, and LIP
expression in nuclear lysates from wild-type and Ddit3/ MDSCs at tumor endpoint (right). Densitometric analysis of isoforms from three experiments.
(B) Expression of LAP, LAP*, and LIP in nuclear lysates from tumor MDSCs isolated from PBS and L-NAC-treated 3LL tumor-bearing wild-type mice.
(C) Expression of mature miR-142-3p in tumor MDSCs from wild-type and Ddit3/ 3LL tumor-bearing mice.
(D) DNA-binding ELISA for C/EBPb in MDSCs nuclear lysates. Data from five independent samples per group.
(E) MDSC chromatin obtained from wild-type and Ddit3/mice bearing s.c. 3LL tumors for 17 days was immunoprecipitated with anti-C/EBPb antibodies and
analyzed by RT-PCR for C/EBPb-binding sequences on IL-6 and Arginase I promoters. Data from n = 5 samples per group.
(F) IL-6 levels in whole-cell extracts from wild-type and Ddit3/ tumor MDSCs (left). Percentage of IL-6+ MDSCs in tumor digests 6 hr after i.p. injection of
Brefeldin A (right). Data from n = 5 samples per group.
(G) STAT3 phosphorylation in wild-type and Ddit3/ tumor MDSCs.
(H) Tumor growth in wild-type or Ddit3/ mice injected with mock or IL-6-overexpressing 3LL cells. Symbols are as follows: 3LL mock in wild-type (closed
square) and in Ddit3/ (closed triangle) mice; 3LL-IL-6 in wild-type (open square) and in Ddit3/ (open triangle) mice.
(I) T cell proliferation after coculture with tumor MDSCs from wild-type and Ddit3/mice bearing s.c. mock or IL-6-overexpressing 3LL cells. T cell proliferation
plotted at a coculture dilution of 1:1/4 T cells:MDSCs.
(J) STAT3 phosphorylation in MDSCs from wild-type or Ddit3/ mice injected with mock or IL-6-overexpressing 3LL tumors.
Data was expressed as mean ± SE from a representative experiment of three experiments unless otherwise stated. NS, nonsignificant; *p < 0.05, **p < 0.01,
***p < 0.001. See also Figure S5.
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suppression remains unknown. In this study, we aimed to deter-
mine the interaction between tumor-linked stress and antitumor
immunity. Our data suggest a new role of Chop as a mediator of
tumor-induced anergy through themodulation of MDSC function
and accumulation.
Chop expression is typically associatedwith pathways leading
to cellular apoptosis. In fact, silencing of Chop in tumor cells
induced resistance to cell death by various chemotherapy
agents (Scho¨nthal, 2013). In addition to its proapoptotic effect
in tumor cells, Chop also regulated cell death processes in
primary myeloid populations. Deletion of Chop decreased398 Immunity 41, 389–401, September 18, 2014 ª2014 Elsevier Inc.apoptosis in liver and fat tissue macrophages from mice
exposed to high-fat diet (Grant et al., 2014; Malhi et al., 2013).
Moreover, low numbers of apoptotic CD11b+ cells were found
in the intestinal mucosa of Ddit3/ mice undergoing colitis,
which correlated with a decreased disease progression (Namba
et al., 2009). We show that Chop deletion inhibited MDSC turn-
over but also changed MDSC immune-suppressive function
into one that promotes antitumoral T cell responses, suggesting
the role of Chop as a central mediator of the inflammatory func-
tion in MDSCs. Accordingly, low levels of MDSC-linked cyto-
kines were detected in Ddit3/ mice having spontaneous liver
carcinomas (Scaiewicz et al., 2013; DeZwaan-McCabe et al.,
Immunity
Regulation of MDSC Function by Tumor-Linked Stress2013). Moreover, Ddit3/ mice were protected against inflam-
matory damage after lipopolysaccharide (LPS)-induced lung
injury (Endo et al., 2006). In contrast to our results, previous
studies suggested an increased tumor node formation in
Ddit3/ mice and increased kidney inflammation after LPS-
induced kidney injury (Esposito et al., 2013; Huber et al., 2013).
These opposite results could be explained by a differential role
of MDSCs in particular inflammation models and the potential
expression of Chop in other cell populations, including tumor
cells. Previous studies showed the upregulation of Chop in
T cells cocultured with IDO-expressing pDCs (Munn et al.,
2005). Unexpectedly, although T cells were the ultimate media-
tors of the antitumor responses induced by Chop deletion, we
did not detect significant levels of Chop in tumor-linked T cells.
However, we do not discard a potential direct effect of Chop
on T cells under specific stress-related conditions.
Inflammatory function of MDSCs is highly dependent on
C/EBPb and phospho-STAT3 (Sonda et al., 2011). C/EBPb
LAP and LAP* are major transcriptional activators of IL-6 (Hattori
et al., 2003), while IL-6 plays a major role in the induction of
phospho-STAT3 (Schafer and Brugge, 2007). We found a
preferential expression of C/EBPb inhibitory form LIP in Ddit3/
MDSCs, which correlated with low levels of IL-6 and phospho-
STAT3. This suggests the upstream role of Chop in the regulation
of master MDSC mediators. A recent study showed the regula-
tion of IL-6 by Chop in LPS-treated macrophages (Liu et al.,
2014). Our results show the critical role of the decrease in IL-6
in the antitumor effects induced by Chop deletion. However,
the effect of LIP in the low IL-6 production found in Ddit3/
MDSCs and the pathways by which Chop deletion leads to
LIP upregulation remain unknown. The specific translation of
C/EBPb LAP, LAP*, or LIP in MDSCs is regulated by the expres-
sion of miR-142-3p (Sonda et al., 2013), which was upregulated
in Ddit3/ MDSCs. Therefore, a potential interaction between
Chop and miR-142-3p could be responsible for the increased
expression of LIP in Ddit3/ MDSCs.
A major question is how MDSCs express Chop without
completely undergoing apoptosis. Atf4 induction by cellular
stress is associatedwith pathwaysmaintaining survival, whereas
Chop is mostly linked to stress-induced cell death. The interac-
tion of prosurvival pathways induced by Atf4 and proapoptotic
signaling linked to Chop is regulated by miR-211, which tran-
siently prevents Chop transcription (Chitnis et al., 2012). How-
ever, it is unknown whether miR-211 plays a role in MDSC
function and turnover. Induction of Chop in MDSCs was medi-
ated by Atf4 and correlated with phosphorylation of eIF2a.
Phospho-eIF2a is induced by the double-stranded RNA-depen-
dent kinase (Pkr), hemin-regulated inhibitor kinase (Hri), PKR-like
ER related kinase (Perk), and general control nonrepressed 2
kinase (Gcn2). Exposure of tumor cells to high levels of ROS
led to endoplasmic reticulum (ER) stress, activation of Perk,
and induction of Chop (Harding et al., 2003; Avivar-Valderas
et al., 2011). Furthermore, induction of ER stress in tumor cells
promoted the expression of chronic inflammatory mediators in
myeloid cells (Mahadevan et al., 2011). Interestingly, Perk dele-
tion in tumor cells prevented tumor growth, which correlated
with low inflammation and sensitivity to stress mediators (Bi
et al., 2005; Bobrovnikova-Marjon et al., 2010; Hart et al.,
2012). However, the effect of ER stress and Perk in MDSC func-Imtion remains to be identified. Initial findings suggest the role of ER
stress in the modulation of MDSC survival through expression of
DR5 (Condamine et al., 2014). Chop induction, especially by
starvation-mediated mechanisms, could also be mediated
through Gcn2. Therefore, understanding the role of eIF2a ki-
nases in the induction of Chop in MDSCs is critical to determine
the effect of tumor stress in antitumor immunity.
Although there are no current therapies to block Chop, some
therapeutic possibilities could include the inhibition or scav-
enging of ROS and/or PNT (Bronte et al., 2005; Corzo et al.,
2009; De Santo et al., 2005; Lu et al., 2011; Sawant et al.,
2013). Indeed, treatment with L-NAC reduced tumor growth
and blocked Chop expression in MDSCs. Thus, further investi-
gation of the links between tumor-linked stress and ISR check-
points are expected to enable the therapeutic inhibition of
Chop. In summary, our data demonstrate the central role of
Chop in MDSC suppressive activity and suggest the feasibility
of overcoming tumor-induced MDSC suppression by blocking
Chop.
EXPERIMENTAL PROCEDURES
Mice and Cell Lines
C57BL/6mice (6- to 8-week-old females) were obtained fromHarlan.Ddit3/,
Gp91phox/, and Atf4+/ mice were purchased from the Jackson Labora-
tories. 3LL lung carcinoma, B16 melanoma, MCA-38 colon carcinoma, and
EL-4 thymoma cells (American Type Culture Collection) were injected s.c.
into the mice and tumor volume measured and calculated using the formula
[(small diameter)2 3 (large diameter) 3 0.5]. Experiments using animals and
samples from patients were approved by the LSU-IACUC and the LSU-IRB
and were performed following the corresponding LSU guidelines. Ovalbumin
or IL-6-expressing 3LL cells (3LL-OVA, or 3LL-IL-6) were generated by trans-
fection using Lipofectamine 2000 (Life Technologies) with vectors coding for
cytosolic chicken ovalbumin or IL-6 and harboring a neomycin resistance
cassette (Addgene). Single 3LL clones were selected in medium supple-
mented with 500 mg/ml Geneticin. BM MDSCs were generated by culturing
BM cells for 3 days in the presence of G-CSF (100 ng/ml) and GM-CSF
(20 ng/ml). For MDSC depletion, 200 mg anti-Gr-1 antibody (clone RB6-8C5,
BioXcell) was administered i.p. on day 0 and every 4th day until endpoint.
For CD4+ or CD8+ T cell depletion studies, mice were pretreated 24 hr before
tumor injection with 400 mg anti-CD4 (clone GK1.5) or anti-CD8 (clone 53.6.72).
Maintenance doses of the depleting antibodies were given twice a week.
Cytotoxic effects of tumor MDSCs on 3LL cells in vitro were determined by
nonradioactive cytotoxicity assay using LDH (Promega). L-NAC (1 mg/kg/
day) was injected i.p. starting at day 1 after tumor injection.
Antibodies
The detailed list of the antibodies used is available in the Supplemental Exper-
imental Procedures.
Bone Marrow Chimeras
Recipient mice lethally irradiated with 950 radswere reconstitutedwith 13 107
BM cells and 13 106 splenocytes from donormice. Chimeric engraftment was
verified in peripheral blood 7weeks after transplantation bymonitoring the cor-
responding switch from CD45.1+ cells into CD45.2+ or from CD45.2+ into
CD45.1+ using flow cytometry. A week later, mice were injected s.c. with
3LL tumor cells.
Tolerogenic Effect of MDSCs
CD8+ T cells (53 106) fromCD45.2+ OT-I mice were adoptively transferred into
CD45.1+ mice. Two days later, MDSCs were sorted from 3LL tumor-bearing
wild-type or Ddit3/ mice and pulsed with 2 mg/ml SIINFEKL for 1 hr, and
5 3 106 MDSCs were transferred i.v. into the mice previously injected with
OT-I. The same day, mice received s.c. vaccination with 4 3 106 DCs gener-
ated from BM cultured for 6 days in media containing GM-CSF (20 ng/ml)munity 41, 389–401, September 18, 2014 ª2014 Elsevier Inc. 399
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Regulation of MDSC Function by Tumor-Linked Stressand IL-4 (10 ng/ml). During the final 24 hr of culture, DCs were exposed to
2 mg/ml SIINFEKL and 1 mg/ml LPS. Mice received a second injection with
SIINFEKL-pulsed MDSCs 5 days later. Twelve days after the initial DCs immu-
nization, draining lymph nodes were recovered and challenged with SIINFEKL
for 24 hr, after which they weremonitored for IFN-g production by Elispot (R&D
Systems).
Adoptive Cellular Therapy
CD45.2+ wild-type orDdit3/mice were injected with 3LL-OVA cells (13 106)
at day 0 or at stratified time points to achieve tumor of similar palpable volume.
Mice then received adoptive transfer of 53 106 CD45.1+CD8+OT-I cells via tail
vein. The following day, mice were vaccinated s.c. with 100 mg of SIINFEKL
peptide in 0.2 ml of PBS. Ten days later, spleens and tumors were tested for
transferred OT-I cells and function.
IL-6 Production in MDSCs
For analysis of IL-6 production in MDSCs, tumor-bearing mice were injected
i.p. with 0.25 mg of Brefeldin A for 6 hr, after which tumors were isolated
and MDSCs tested for IL-6 by flow cytometry. To assess IL-6 signaling, BM
MDSCs were developed using BM cells from wild-type and Ddit3/ mice.
On protocol day 3, recombinant mouse IL-6 (R&D Systems) was supple-
mented to the culture at 50 ng/ml for 8 hr.
MDSC Suppressive Mechanism Assays
Superoxide production was quantified in freshly isolated MDSCs using the
Superoxide Anion Assay Kit (Sigma). Peroxynitrite levels were determined in
tissue or MDSCs lysates using a Nitrotyrosine ELISA Assay (EMD Millipore).
C/EBPb Activity
Nuclear extracts from MDSCs were tested for C/EBPb DNA binding activity
using the TransAM C/EBPb DNA-binding ELISA kit (Active Motif).
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.immuni.2014.08.015.
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